We’re excited to present the Inaugural Issue of Immunotherapy Advances, the first fully Open Access journal of the British Society for Immunology. Immunotherapy Advances is edited by globally-renowned experts in the field who have been working hard over the past few months to bring you a collection of high-quality articles spanning the translational pipeline for immunotherapy.
The first published content of the journal features an Introductory Editorial from the Founding Editor-in-Chief, Professor Tim Elliott. In this piece, Professor Elliott frames the current immunotherapy landscape and looks forward to the exciting developments expected in the field over the next few years.
We’d like to encourage everyone to read this Editorial for a preview of the brilliant content published so far, including three cutting-edge research articles, insightful commentaries, informative reviews and the first article of the journal’s TrialsWatch series.
The Immunotherapy Advances TrialsWatch series aims to provide a timely review of the progress of immunotherapy clinical trials in a specific area. We’re delighted to see a TrialsWatch article at launch published by members of the BSI Inflammation Affinity Group, and more from our Affinity Groups coming soon!
We invite our members and the wider immunology community to take a look at the accepted versions of the initial articles of our first fully Open Access journal. Access the first published content of Immunotherapy Advances here.
A note from Founding Editor-in-Chief of Immunotherapy Advances, Professor Tim Elliott FRSB, FMedSci:
“There has never been a better time to launch a new journal to serve the field of immunotherapy. I am proud to present the Inaugural Issue of Immunotherapy Advances featuring outstanding research from field leaders, accompanied by insightful commentaries and reviews and complemented with our TrialsWatch series, providing excellent examples of the type of content we’re looking to publish in the journal.
“I am delighted to be working with six international Regional Editors to bring you the very best research spanning the translational pipeline from discovery research and preclinical models through to clinical trials. I hope you will join me in supporting the British Society for Immunology to ensure that Immunotherapy Advances becomes a leading journal in the field.”
FIND OUT MORE
- Visit the official Immunotherapy Advances website
- Join the conversation online by following @IMTadvances on Twitter
- Be one of the first authors to publish in Immunotherapy Advances - submit your work
- Find out more about Professor Elliott’s background, what attracted him to the role of Editor-in-Chief and his vision for the journal in this interview
- Discover the brilliant Regional Editors in this article looking into their areas of expertise, career roadmap and the type of research they hope to see published
- Keep up to date by signing up to receive email alerts when content is published*
Immunotherapy Advances is an official journal of the British Society for Immunology and, as such, has joined our two established hybrid journals, Immunology and Clinical & Experimental Immunology, as part of the BSI journal family. We’re proud to offer a 20% discount on publication fees in Immunotherapy Advances for BSI members. All BSI members are eligible for a discounted Article Processing Charge (APC) of £1,600.
*The email alerting service is from our publisher, Oxford University Press.